Seeking Alpha

Par Pharma (PRX) +6.5% after a Delaware court rules five patents covering Santarus' (SNTS...

Par Pharma (PRX) +6.5% after a Delaware court rules five patents covering Santarus' (SNTS -31.9%) stomach drug Zegerid are invalid due to "obviousness." Analysts say Par Pharma's proposed generic is Zegerid's only challenger, and while it hasn't received FDA approval, the ruling removes a large hurdle.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|